SCHEMBL31339975

SCHEMBL31339975

Cc1cnc(NC(=O)c2cccc(C(F)(F)F)c2)nc1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.53
▸ LCK P06239 9/20 0.49
▸ KDR P35968 3/20 0.49
▸ MAPK14 Q16539 3/20 0.49
▸ JAK3 P52333 2/20 0.49
▸ TEK Q02763 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ BTK Q06187 7/20 0.47
▸ CSF1R P07333 1/20 0.46
▸ KIT P10721 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ BLK P51451 1/20 0.45
▸ BRAF P15056 1/20 0.45
▸ KCNQ3 O43525 1/20 0.45
▸ KCNQ2 O43526 1/20 0.45
▸ KCNE1 P15382 1/20 0.45
▸ KCNQ1 P51787 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31339981 0.91 ALDH1A1 (0.43) TRPV1ALDH1A1MAPT
SCHEMBL31339943 0.89 TRPV1 (0.48) TRPV1ALDH1A1MAPT
SCHEMBL31339962 0.87 LCK (0.59) TRPV1LCKKDRMAPK14JAK3
SCHEMBL31339990 0.79 SORT1 (0.50) TRPV1LCKTEKBTK
SCHEMBL31339978 0.78 BTK (0.48) TRPV1LCKBTKPTGS1
SCHEMBL31339996 0.77 CLK1 (0.47) JAK3MAPT
SCHEMBL5000446 0.77 RAF1 (0.61) TRPV1LCKKDRMAPK14JAK3
SCHEMBL16246847 0.76 GPR17 (0.69) PTGS1MAPTKCNQ3KCNQ2KCNE1
SCHEMBL31340007 0.75 PTGS1 (0.54) TRPV1BTKKITPTGS1
SCHEMBL30354767 0.75 PTGS1 (0.67) GAAPTGS1ALDH1A1MAPTKCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF JILIN UNIVERSITY (CN) 2026-05-07 — — US disclosed
EP-4725485-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF Jilin University (CN) 2026-04-15 — — EP disclosed
CN-119285557-A CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof 吉林大学 2025-01-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF GZMB, CD74, GSDMD TRPV1 1150/4885LCK 1036/4885KDR 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback